Cargando…

Targeting the tumor stroma for cancer therapy

Tumors are comprised of both cancer cells and surrounding stromal components. As an essential part of the tumor microenvironment, the tumor stroma is highly dynamic, heterogeneous and commonly tumor-type specific, and it mainly includes noncellular compositions such as the extracellular matrix and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Maosen, Zhang, Tao, Xia, Ruolan, Wei, Yuquan, Wei, Xiawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628074/
https://www.ncbi.nlm.nih.gov/pubmed/36324128
http://dx.doi.org/10.1186/s12943-022-01670-1
_version_ 1784823117702496256
author Xu, Maosen
Zhang, Tao
Xia, Ruolan
Wei, Yuquan
Wei, Xiawei
author_facet Xu, Maosen
Zhang, Tao
Xia, Ruolan
Wei, Yuquan
Wei, Xiawei
author_sort Xu, Maosen
collection PubMed
description Tumors are comprised of both cancer cells and surrounding stromal components. As an essential part of the tumor microenvironment, the tumor stroma is highly dynamic, heterogeneous and commonly tumor-type specific, and it mainly includes noncellular compositions such as the extracellular matrix and the unique cancer-associated vascular system as well as a wide variety of cellular components including activated cancer-associated fibroblasts, mesenchymal stromal cells, pericytes. All these elements operate with each other in a coordinated fashion and collectively promote cancer initiation, progression, metastasis and therapeutic resistance. Over the past few decades, numerous studies have been conducted to study the interaction and crosstalk between stromal components and neoplastic cells. Meanwhile, we have also witnessed an exponential increase in the investigation and recognition of the critical roles of tumor stroma in solid tumors. A series of clinical trials targeting the tumor stroma have been launched continually. In this review, we introduce and discuss current advances in the understanding of various stromal elements and their roles in cancers. We also elaborate on potential novel approaches for tumor-stroma-based therapeutic targeting, with the aim to promote the leap from bench to bedside.
format Online
Article
Text
id pubmed-9628074
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96280742022-11-03 Targeting the tumor stroma for cancer therapy Xu, Maosen Zhang, Tao Xia, Ruolan Wei, Yuquan Wei, Xiawei Mol Cancer Review Tumors are comprised of both cancer cells and surrounding stromal components. As an essential part of the tumor microenvironment, the tumor stroma is highly dynamic, heterogeneous and commonly tumor-type specific, and it mainly includes noncellular compositions such as the extracellular matrix and the unique cancer-associated vascular system as well as a wide variety of cellular components including activated cancer-associated fibroblasts, mesenchymal stromal cells, pericytes. All these elements operate with each other in a coordinated fashion and collectively promote cancer initiation, progression, metastasis and therapeutic resistance. Over the past few decades, numerous studies have been conducted to study the interaction and crosstalk between stromal components and neoplastic cells. Meanwhile, we have also witnessed an exponential increase in the investigation and recognition of the critical roles of tumor stroma in solid tumors. A series of clinical trials targeting the tumor stroma have been launched continually. In this review, we introduce and discuss current advances in the understanding of various stromal elements and their roles in cancers. We also elaborate on potential novel approaches for tumor-stroma-based therapeutic targeting, with the aim to promote the leap from bench to bedside. BioMed Central 2022-11-02 /pmc/articles/PMC9628074/ /pubmed/36324128 http://dx.doi.org/10.1186/s12943-022-01670-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Xu, Maosen
Zhang, Tao
Xia, Ruolan
Wei, Yuquan
Wei, Xiawei
Targeting the tumor stroma for cancer therapy
title Targeting the tumor stroma for cancer therapy
title_full Targeting the tumor stroma for cancer therapy
title_fullStr Targeting the tumor stroma for cancer therapy
title_full_unstemmed Targeting the tumor stroma for cancer therapy
title_short Targeting the tumor stroma for cancer therapy
title_sort targeting the tumor stroma for cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628074/
https://www.ncbi.nlm.nih.gov/pubmed/36324128
http://dx.doi.org/10.1186/s12943-022-01670-1
work_keys_str_mv AT xumaosen targetingthetumorstromaforcancertherapy
AT zhangtao targetingthetumorstromaforcancertherapy
AT xiaruolan targetingthetumorstromaforcancertherapy
AT weiyuquan targetingthetumorstromaforcancertherapy
AT weixiawei targetingthetumorstromaforcancertherapy